CLINICAL_TRIALS trial_result · 2021-07-23

Clinical Trial Update: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 [Phase 4]

Phase IIIB-IV long-term follow-up study for CAMMS03409 in relapsing-remitting multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Genzyme, a Sanofi Company | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2021-07-23